IMM-101 is a type of immune-stimulating vaccine that was originally developed for the treatment of cancer. However, researchers have found that it may also help in preventing severe COVID-19 infections among patients being treated for cancer.
IMM-101 uses an inactivated version of a bacterium called Mycobacterium obuense to activate parts of the immune system that are involved in protecting against viral and bacterial infections. After receiving this vaccine you may be able to fight off these types of infections (such as COVID-19) better.
Participants in this study will be randomly assigned to one of two groups at the time of enrollment:
- Group 1 will receive the IMM-101 vaccine in three doses; received on days 1, 14, and 45
- Group 2 will receive active surveillance. This is called the “control” group.
Many clinical trials include a control group so that researchers can tell whether the effect is due to the treatment, or just reflects the natural behaviour of the disease.
The medication will be administered by injection into the arm.
- Undergoing treatment for cancer
- Must have at least 1 of the following risk factors for COVID-19:
- Over 65 years of age
- High blood pressure
- Chronic conditions affecting the heart, lung, liver or kidneys
- BMI greater than 40
- Living in a nursing home or care facility
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreJuravinski Cancer Centre||Principal InvestigatorRosalyn Anne Juergens||LocationHamilton, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreLondon Regional Cancer Program||Principal InvestigatorEric W. Winquist||LocationLondon, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreOttawa Hospital Research Institute||Principal InvestigatorRebecca Ann Auer||LocationOttawa, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreOdette Cancer Centre||Principal InvestigatorMartin Smoragiewicz||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreUniversity Health Network||Principal InvestigatorGrainne O'Kane||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreCHUM-Centre Hospitalier de l'Universite de Montreal||Principal InvestigatorDavid Roberge||LocationMontreal, QC||Trial StatusRecruiting|
|Hospital / Cancer CentreThe Research Institute of the McGill University||Principal InvestigatorGeorge Zogopoulos||LocationMontreal, QC||Trial StatusRecruiting|